Evidence map›Paper›PMID 18790793›Full record

ArticleProtein engineering, design & selection : PEDS2008

Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.

Claire Germain, Emmanuelle Campigna, Imed Salhi, Sébastien Morisseau, Isabelle Navarro-Teulon, Jean-Pierre Mach, André Pèlegrin, Bruno Robert

Open access · bronzeAbstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Claire GermainIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier1, Montpellier F-34298, France.
Emmanuelle Campigna
Imed Salhi
Sébastien Morisseau
Isabelle Navarro-Teulon
Jean-Pierre Mach
André Pèlegrin
Bruno Robert
Inserm · FRUniversité de Montpellier · FRUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are at the crossroad between innate and adaptive immunity and play a major role in cancer immunosurveillance. NK cell stimulation depends on a balance between inhibitory and activating receptors, such as the stimulatory lectin-like receptor NKG2D. To redirect NK cells against tumor cells, we designed bifunctional proteins able to specifically bind tumor cells and to induce their lysis by NK cells, after NKG2D engagement. To this aim, we used the 'knob into hole' heterodimerization strategy, in which 'knob' and 'hole' variants were generated by directed mutagenesis within the CH3 domain of human IgG1 Fc fragments fused to an anti-CEA or anti-HER2 scFv or to the H60 murine ligand of NKG2D, respectively. We demonstrated the capacity of the bifunctional proteins produced to specifically coat tumor cells surface with H60 ligand. Most importantly, we demonstrated that these bifunctional proteins were able to induce an NKG2D-dependent and antibody-specific tumor cell lysis by murine NK cells. Overall, the results show the possibility to redirect NK cytotoxicity to tumor cells by a new format of recombinant bispecific antibody, opening the way of potential NK cell-based cancer immunotherapies by specific activation of the NKG2D receptor at the tumor site.

Indexed as

Cytotoxicity, ImmunologicAnimalsBlotting, WesternCell DeathCell Line, TumorElectrophoresis, Gel, Two-DimensionalGPI-Linked ProteinsHumansIntercellular Signaling Peptides and ProteinsKiller Cells, Lymphokine-ActivatedKiller Cells, NaturalMiceMinor Histocompatibility AntigensRecombinant ProteinsTumor Cells, CulturedGPI-Linked ProteinsIntercellular Signaling Peptides and Proteinsminor H antigen H60Minor Histocompatibility AntigensRecombinant ProteinsULBP2 protein, human

Identifiers

PMID18790793
PMCPMC2759461
OpenAlexW2139691488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.